Vera Therapeutics VERA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$368.95M-110% | -$299.62M-96.9% | -$251.94M-87.5% | -$218.28M-102% | -$175.46M-86.1% | ||
| $523K+192% | $468K+346% | $388K+619% | $283K+686% | $179K-66.7% | ||
| $43.39M+77.7% | $37.93M+82.3% | $33.18M+86.3% | $29.02M+91.7% | $24.42M+88.6% | ||
| $4.35M— | $13.91M— | —— | —— | —— | ||
| $18.79M— | $14.44M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $1.11M-44.7% | $1.45M-29.8% | $1.88M-8.0% | $1.95M-7.4% | $2M-7.3% | ||
| -$1.27M+41.3% | -$1.48M+38.4% | -$1.91M+24.3% | -$2.01M+21.5% | -$2.16M+16.8% | ||
| —— | —— | —— | -$487K— | -$359K— | ||
| -$293.2M-88.8% | -$241.1M-79.0% | -$210.29M-74.3% | -$185.27M-73.6% | -$155.26M-55.7% | ||
| $466K-59.8% | $630K-35.2% | $1.17M+201% | $1.28M+741% | $1.16M+1,740% | ||
| $41.15M+118% | $194.29M+142% | -$107.76M— | -$177.52M— | -$228.74M— | ||
| —— | —— | —— | —— | —— | ||
| $9.39M+16.9% | $6.98M-48.0% | $5.11M-54.4% | $5.06M-52.9% | $8.04M+4.0% | ||
| $311.31M-6.1% | $308.9M-49.1% | $348.57M+14.1% | $348.51M+14.2% | $331.67M+9.8% | ||
| $59.26M+523% | $262.08M+458% | $30.52M+16,596% | $24.04M+373% | -$14.02M+79.6% | ||
| $6.77M+0.9% | $6.72M+1.0% | $6.67M+14.1% | $6.64M+33.5% | $6.71M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $842K— | ||
| -$1.27M+41.3% | -$1.48M+38.4% | -$1.91M+24.3% | -$2.01M+21.5% | -$2.16M+16.8% | ||
| —— | —— | —— | -$487K— | -$359K— | ||
| —— | —— | —— | —— | —— | ||
| $1.11M-44.7% | $1.45M-29.8% | $1.88M-8.0% | $1.95M-7.4% | $2M-7.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $9.39M+16.9% | $6.98M-48.0% | $5.11M-54.4% | $5.06M-52.9% | $8.04M+4.0% | ||
| —— | —— | —— | —— | —— | ||
| -$1.27M+41.3% | -$1.48M+38.4% | -$1.91M+24.3% | -$2.01M+21.5% | -$2.16M+16.8% | ||
| —— | $252K— | $189K— | $126K— | $63K— | ||
| —— | —— | —— | —— | —— | ||
| -$293.66M-87.7% | -$241.73M-78.2% | -$211.47M-74.7% | -$186.55M-74.5% | -$156.41M-56.8% | ||
| -$293.66M-87.7% | -$241.73M-78.2% | -$211.47M-74.7% | -$186.55M-74.5% | -$156.41M-56.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Vera Therapeutics's cash flow data come from?
- Every line is extracted from Vera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.